Goldacre Clashes With Pharma Over Trial Data Transparency
Executive Summary
The pharmaceutical industry is proud of its 'forward-looking approach' to clinical trial transparency and hopes that it will help answer new research questions. But transparency campaigner Ben Goldacre has stirred controversy by saying that industry is wasting money on sharing patient-level data.
You may also be interested in...
Pharma ‘Doing The Right Thing By Patients,’ Major Trial Transparency Study Finds
Authors of new a study find that while most pharma companies are complying with rules for reporting trial results on the EU Clinical Trials Register, too many trials are still not being reported. They hope their newly launched online EUTrialsTracker tool might help address the situation.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.